{"id":"W4387320133","doi":"10.48083/vsqg7437","title":"Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Ipsen; Eisai; University of Cambridge; American Society of Clinical Oncology; AstraZeneca; American College of Radiology Imaging Network; U.S. Department of Defense; Exelixis; Pfizer; ECOG-ACRIN Cancer Research Group; National Cancer Institute; Macmillan Cancer Support","keywords":"Medicine; Adjuvant therapy; Adjuvant; Renal cell carcinoma; Perioperative; Oncology; Kidney cancer; Neoadjuvant therapy; Targeted therapy; Internal medicine; Pazopanib; Systemic therapy; Disease; Cancer; Sunitinib; Surgery; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005507875,0.00009488747,0.0003405275,0.0003400955,0.0001165638,0.0003113573,0.0001264659,0.0001916618,0.00117339],"category_scores_gemma":[0.001216079,0.00004605307,0.0002836174,0.0003558977,0.0001539647,0.0002111098,0.000137461,0.0004090805,0.0001955798],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003203358,"about_ca_system_score_gemma":0.0006298819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002998738,"about_ca_topic_score_gemma":0.001389985,"domain_scores_codex":[0.9997643,0.0001260469,0.00003948109,0.00001515081,0.00004242818,0.00001265915],"domain_scores_gemma":[0.9995946,0.000231169,0.00009171534,0.00001187557,0.00003924583,0.00003139268],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001587338,0.0001848002,0.007240299,0.008490085,0.000318995,0.0004096551,0.00007844552,0.0008011415,0.003945341,0.002777381,0.01492169,0.9592448],"study_design_scores_gemma":[0.0006146297,0.004743614,0.06640397,0.01608499,0.00161645,0.009507277,0.0002233959,0.001133082,0.006860636,0.004925278,0.8878266,0.00006007992],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01819238,0.9708445,0.0007144388,0.002521197,0.0005862237,0.00003168143,0.0001316881,0.00001310676,0.006964763],"genre_scores_gemma":[0.2016413,0.7898461,0.002199808,0.002070344,0.001499081,0.0001350785,0.0003800049,0.000009171512,0.002219143],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00117339,"threshold_uncertainty_score":0.003925323,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0473745344043642,"score_gpt":0.3049040047929303,"score_spread":0.2575294703885662,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}